

201030007A (2/2)

厚生労働科学研究費補助金

肝炎等克服緊急対策研究事業

データマイニング手法を用いた効果的な治療方法
に関する研究

平成22年度

総括研究報告書
分担研究報告書
(2/2)

論 文 集

研究代表者

八 橋 弘

平成 23 (2011) 年 3 月

厚生労働科学研究費補助金

肝炎等克服緊急対策研究事業

データマイニング手法を用いた効果的な治療方法
に関する研究

平成22年度

総括研究報告書
分担研究報告書
(2/2)

論 文 集

研究代表者

八 橋 弘

平成 23(2011)年 3 月

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tateyama M, <u>Yatsubashi H</u> , Taura N, Motoyoshi Y, Nagaoka S, Yanagi K, Abiru S, Yano K, Komori A, Migita K, Nakamura M, Nagahama H, Sasaki Y, Miyakawa Y, Ishibashi H.	Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus	J Gastroenterol.	46(1)	92-100	2011
Taura N, Fukushima N, <u>Yastubashi H</u> , Takami Y, Seike M, Watanabe H, Mizuta T, Sasaki Y, Nagata K, Tabara A, Komorizono Y, Taketomi A, Matsumoto S, Tamai T, Muro T, <u>Nakao K</u> , Fukuizumi K, Maeshiro T, Inoue O, Sata M.	The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area	Med Sci Monit.	17(2)	PH7-11	2011
Ginya H, Asahina J, Nakao R, Tamada Y, Takahashi M, Yohda M, <u>Yatsubashi H</u> .	Semi-quantitative discrimination of HBV mutants using allele-specific oligonucleotide hybridization with Handy Bio-Strand	J Biosci Bioeng.	109(1)	94-100	2010
Nishiura T, Watanabe H, Yano K, Ito M, Abiru S, Fujimoto T, Komori A, <u>Yatsubashi H</u> , Matsuoka Y, Ishibashi H.	Integrated fibrosis scoring by ultrasonography predicts the occurrence of hepatocellular carcinoma in patients with chronic hepatitis C virus infection	J Med Ultrasonics.	38	13-19	2011
Taura N, Ichikawa T, Miyaaki H, <u>Yatsubashi H</u> , Ishibashi H, <u>Nakao K</u> .	Prevalence of type2 diabetes mellitus in Japanese patients with hepatocellular carcinoma	Experimental and Therapeutic Medicine	2	81-84	2011
Ide T, Sata M, Chayama K, Shindo M, Toyota J, Mochida S, Tomita E, Kumada H, Yamada G, <u>Yatsubashi H</u> , Hayashi N, Ishikawa H, Seriu T, Omata M.	Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy	Hepato Int.	4(3)	594-600	2010
Sakamoto N, Tanaka Y, Nakagawa M, <u>Yatsubashi H</u> , Nishiguchi S, Enomoto N, Azuma S, Nishimura Sakurai Y, Kakinuma S, Nishida N, Tokunaga K, Honda M, Ito K, Mizokami M, Watanabe M.	ITPA gene variant protects against anemia induced by pegylated interferon- α and ribavirin therapy for Japanese patients with chronic hepatitis C	Hepato Res.	40(11)	1063-1071	2010

Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, <u>Yatsubashi H</u> , Izumi N.	Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis	J Gastroenterol.	46(3)	401-409	2011
Kusakabe A, Tanaka Y, Mochida S, Nakayama N, Inoue K, Sata M, Isoda N, Kang JH, Sumino Y, <u>Yatsubashi H</u> , Takikawa Y, Kaneko S, Yamada G, Karino Y, Tanaka E, Kato J, Sakaida I, Izumi N, Sugauchi F, Nojiri S, Joh T, Miyakawa Y, Mizokami M.	Case-control study for the identification of virological factors associated with fulminant hepatitis B	Hepatol Res.	39(7)	648-656	2009
<u>八橋 弘</u>	特集／肝胆膵薬物治療学の進歩－この30年－，ペガシス，コペガス	肝胆膵	61(6)	941-949	2010
橋元 悟， <u>八橋 弘</u>	PEG-IFN＋RBV併用療法における体重あたりRBV総投与量の意義	肝胆膵	61 (Suppl)	119-126	2010
<u>八橋 弘</u> ，橋元 悟，柳謙二	肝炎の臨床，C型肝炎治療無効例に対する再治療	肝疾患Review 2010-2011 [第1版1刷]		176-181	2010
<u>八橋 弘</u>	感染症，ウイルス性肝炎，C型肝炎	別冊日本臨牀新領域別症候群シリーズNo. 13, 肝・胆道系症候群(第2版)－その他の肝・胆道系疾患を含めて－ I 肝臓編(上)		19-23	2010
<u>八橋 弘</u> ，長岡進矢，阿比留正剛	B型肝炎に対するIFN治療	総合臨牀	60(1)	81-86	2011
<u>八橋 弘</u>	特集／わが国におけるHBVキャリアー自然経過、治療の有無を含めて－	Expert Opinion on Hepatitis B	Vol.10	6-9	2010
<u>八橋 弘</u> ，斐 成寛，長岡進矢，阿比留正剛	ウイルス感染症，B型肝炎ウイルスDNAおよび核酸検査	日本臨牀	68(増6)	443-445	2010
Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, <u>Mita E</u> , Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, and Hayashi N.	Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy	J Hepatol.	54(4)	604-611	2011

Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Fukuda K, Mita E , Haruna Y, Inoue A, Imai Y, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.	Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin	J Med Virol.	83(3)	419-427	2011
Tatsumi T, Takehara T, Miyagi T, Nakazuru S, Mita E , Kanto T, Hiramatsu N, Hayashi N.	Hepatitis C virus-specific CD8+ T cell frequencies are associated with the responses of pegylated interferon- α and ribavirin combination therapy in patients with chronic hepatitis C virus infection	Hepatology Res.	41(1)	30-38	2011
M. Yagura , A. Tanaka, H. Kamitsukasa, H. Otsuka, S. Kanno, T. Aoyama.	Re-evaluation of the serum aminotransferase upper normal limit in chronic hepatitis C patients	Internal Medicine	49(6)	525-528	2010
正木尚彦 , 伊藤清頭, 溝上雅史	HCV治療の有効性とIL28B (インターフェロン λ)	感染・炎症・免疫	40(4)	72-75	2011
平嶋 昇, 島田昌明 , 岩瀬弘明, 後藤秀実	前インターフェロン不応C型慢性肝炎に対する二重濾過血漿交換併用ペグインターフェロン・リバビリン療法の初期効果—第1報—	肝臓	50(12)	738-740	2009
Akahoshi H, Taura N, Ichikawa T, Miyaaki H, Akiyama M, Miura S, Ozawa E, Takeshita S, Muraoka T, Matsuzaki T, Ohtani M, Isomoto H, Matsumoto T, Takeshima F, Nakao K .	Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma	Oncol Rep.	23(5)	1317-1323	2010

Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus

Masakuni Tateyama · Hiroshi Yatsushashi · Naota Taura · Yasuhide Motoyoshi · Shinya Nagaoka · Kenji Yanagi · Seigo Abiru · Koji Yano · Atsumasa Komori · Kiyoshi Migita · Minoru Nakamura · Hiroyasu Nagahama · Yutaka Sasaki · Yuzo Miyakawa · Hiromi Ishibashi

Received: 4 August 2009 / Accepted: 6 July 2010 / Published online: 14 August 2010
© Springer 2010

Abstract

Background Noninvasive risk factors are required for predicting the development of hepatocellular carcinoma (HCC) not only in patients with cirrhosis but also in those with chronic hepatitis who are infected with hepatitis C virus (HCV).

Methods A total of 707 patients with chronic HCV infection without other risks were evaluated for the predictive value of noninvasive risk factors for HCC, including age, sex, viral load, genotype, fibrosis stage, aspartate and alanine aminotransferase levels, bilirubin, albumin, platelet count, and alpha-fetoprotein (AFP) at entry to the study, as well as interferon (IFN) therapy they received.

Results The ten-year cumulative incidence rates of HCC for patients with fibrosis stages F0/F1, F2, F3, and F4 were 2.5, 12.8, 19.3, and 55.9%, respectively. Multivariate analysis identified age ≥ 57 years [hazard ratio (HR) 2.026, $P = 0.004$], fibrosis stage F4 (HR 3.957, $P < 0.001$), and AFP 6–20 ng/mL (HR 1.942, $P = 0.030$) and ≥ 20 ng/mL (HR 3.884, $P < 0.001$), as well as the response to IFN [relative risk (RR) 0.099, $P < 0.001$], as independent risk

factors for the development of HCC. The ten-year cumulative incidence rates of HCC in the patients with AFP levels of < 6 , 6–20, and ≥ 20 ng/mL at entry were 6.0, 24.6, and 47.3%, respectively.

Conclusions Not only high (> 20 ng/mL), but also even slightly elevated (6–20 ng/mL) AFP levels, could serve as a risk factor for HCC to complement the fibrosis stage. In contrast, AFP levels < 6 ng/mL indicate a low risk of HCC development in patients infected with HCV, irrespective of the fibrosis stage.

Keywords Alpha-fetoprotein · Hepatitis C virus · Hepatocellular carcinoma

Introduction

Worldwide, an estimated 170 million people are persistently infected with hepatitis C virus (HCV) [1, 2], and they are at high risk of developing hepatocellular carcinoma (HCC) [1, 3–5]. Several factors have been identified that increase the risk of HCC, including, age, male gender, and alcohol intake, as well as cirrhosis and the duration of infection [3, 5]. Of these factors, the stage of liver fibrosis parallels the risk for HCV-associated HCC. The annual incidence of HCC in patients with HCV-related cirrhosis ranges from 1 to 7% [6, 7]. Although liver biopsy is the gold standard for the assessment of hepatic fibrosis [8, 9], it is too invasive a procedure to be acceptable as a routine test [10, 11]. In place of liver biopsy, the platelet count is used to estimate the degree of fibrosis [12–14], and low platelet counts have been shown to be a risk factor for the development of HCC in cirrhotic patients [13, 15, 16]. In this study, we tried to identify noninvasive markers for predicting the development of HCC in a large cohort of

M. Tateyama · H. Yatsushashi (✉) · N. Taura · Y. Motoyoshi · S. Nagaoka · K. Yanagi · S. Abiru · K. Yano · A. Komori · K. Migita · M. Nakamura · H. Ishibashi
Clinical Research Center, National Nagasaki Medical Center,
Nagasaki 856-8562, Japan
e-mail: yatsushashi@nmc.hosp.go.jp

M. Tateyama · H. Nagahama · Y. Sasaki
Department of Gastroenterology and Hepatology,
Graduate School of Medical Sciences, Kumamoto University,
Kumamoto 860-8556, Japan

Y. Miyakawa
Miyakawa Memorial Research Foundation,
Tokyo 107-0062, Japan

patients with chronic HCV infection during a long observation period.

Patients and methods

Study design

Between January 1992 and December 2003, 832 patients were identified who were positive for both anti-HCV, by a second or third-generation enzyme-linked immunosorbent assay (ELISA), and for HCV RNA by polymerase chain reaction (PCR). These patients underwent liver biopsy guided by ultrasonography (US) at the National Nagasaki Medical Center. Of the 832 patients, 125 (15.0%) were excluded according to the following criteria: (1) positive for hepatitis B surface antigen (HBsAg) ($n = 12$); (2) heavy habitual drinking defined as an average daily consumption of >100 g ethanol ($n = 26$); (3) presence of autoimmune hepatitis (AIH), primary biliary cirrhosis, or idiopathic portal hypertension ($n = 8$); (4) positive anti-nuclear antibody (defined as a titer of $>320\times$) without a diagnosis of AIH ($n = 8$); or (5) a short follow-up period (<180 days) ($n = 71$). The remaining 707 patients were analyzed retrospectively for the incidence of HCC. Their medical histories had been recorded, with the results of routine tests for blood cell counts, liver biochemical parameters, and markers for HCV infection at the time of US-guided liver biopsy at regular intervals. Complete blood cell counts and biochemical tests were performed, using automated procedures, at the clinical pathology laboratories of the National Nagasaki Medical Center. Informed consent was obtained from each patient included in the study, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a-priori approval by the institution's human research committee.

Staging of hepatic fibrosis

Liver biopsy was taken by fine-needle aspiration (18G or 16G sonopsy) guided by US. Liver tissue specimens were fixed in 10% formalin, embedded in paraffin, and stained with hematoxylin and eosin. They were evaluated for the stage of hepatic fibrosis by a pathologist according to the criteria of Desmet et al. [17].

HCV RNA, HCV core antigen, and HCV genotypes

HCV RNA was determined by reverse transcriptase (RT)-PCR using a commercial kit (Amplicor HCV; Roche Diagnostic Systems, Basel, Switzerland). HCV core antigen was determined using the lumispot EIKEN HCV

antigen assay (Eiken Chemicals, Tokyo, Japan). HCV core antigen levels were classified as low or high with the cutoff at 1,000 fmol/L [18, 19]. Genotypes of HCV were determined by RT-PCR with genotype-specific primers (HCV RNA core genotype; Roche Diagnostics, Tokyo, Japan) [20, 21].

Interferon therapy

During the observation period, 373 of the 707 (52.8%) patients received interferon (IFN) monotherapy, pegylated (PEG)-IFN monotherapy, combination therapy with IFN and ribavirin, or PEG-IFN and ribavirin. Sustained virological response (SVR) was defined as the absence of detectable HCV RNA by the end of treatment that persisted for longer than 6 months thereafter, while failure in meeting these criteria was judged as non-SVR. There was no relapse of viremia after 6 months among SVR patients.

Diagnosis of hepatocellular carcinoma

Patients were followed up with hematological and biochemical tests at intervals of 1–12 months. Liver imaging was performed by US at 6- to 12-month intervals in most patients at fibrosis stages F0–F2, while computed tomography (CT), magnetic resonance imaging (MRI), or US was performed at 3- to 6-month intervals in patients at fibrosis stages F3 and F4. HCC was diagnosed by typical vascular patterns on CT, MRI, or angiography, or by fine-needle biopsy of space-occupying lesions detected in the liver.

Statistical analysis

Continuous variables [platelet counts, albumin, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alpha-fetoprotein (AFP), HCV core antigen] were dichotomized with respect to the median value or clinically meaningful values in a multivariate analysis. To estimate the cumulative risk of developing HCC, the Kaplan–Meier method and the log-rank test were used. Cox proportional hazards regression analysis was performed to evaluate risk factors for HCC. Analysis was performed by Bonferroni's correction and data analysis was performed with SPSS ver. 11.0 (SPSS, Chicago, IL, USA).

Results

Characteristics at enrollment

Table 1 lists the characteristics of the 707 patients at enrollment. The median age was 57.0 years; 120 (17.0%)

Table 1 Demographic, clinical, and virological characteristics of 707 patients persistently infected with hepatitis C virus (HCV)

Age (years)	57.0 (19–79)
Male	351 (49.6%)
Observation period (years)	8.2 ± 4.4 ^a
Interferon therapy	373 (52.8%)
Habitual alcohol intake	135 (19.1%)
Fibrosis stage	
F0/F1	273 (38.6%)
F2	193 (27.3%)
F3	121 (17.1%)
F4	120 (17.0%)
Platelet count ($\times 10^3/\text{mm}^3$)	156 (30–391)
Albumin (g/dL)	4.2 (2.7–5.3)
Total bilirubin (mg/dL)	0.7 (0.1–2.5)
Aspartate aminotransferase (AST; IU/L)	53 (11–422)
Alanine aminotransferase (ALT; IU/L)	82 (1–1,057)
Alpha-fetoprotein (AFP; ng/mL)	6 (1–510)
HCV core antigen	
$\geq 1,000$ fmol/L	539 (76.2%)
HCV genotype	
1b	510 (72.1%)
2a/2b	195 (27.6%)
Unknown	2 (0.3%)

Values are medians with ranges in parentheses, or means with SD in parentheses

^a Mean ± SD

patients were diagnosed histologically with liver cirrhosis (fibrosis stage: F4) and the remaining 587 had chronic hepatitis (fibrosis stage F0, F1, F2, or F3). The median value of AFP was 6 ng/mL. The average follow-up period was 8.2 years. The patients were classified into three categories by the level of AFP; 350 patients (49.5%) had AFP levels of <6 ng/mL, 254 (35.9%) had levels between 6 and 20 ng/mL, and the remaining 103 (14.6%) had levels of ≥ 20 ng/mL.

IFN therapy and IFN response

Of the 120 patients with cirrhosis (fibrosis stage F4), 46 (38.3%) received IFN while the remaining 74 (61.7%) did not. The proportions of IFN-treated patients showing an SVR were 40.8% (56/137) in patients with F1; 37.6% (44/117) in those with F2; 32.8% (24/73) in those with F3; and 32.6% (15/46) in those with F4.

Risk factors for HCC

Cox regression analysis was performed on several variables, including age, sex, alcohol consumption, IFN therapy during the observation period, and biochemical as well

as virological parameters. The following factors were identified as showing an increased risk for HCC by the univariate analysis: age; IFN therapy; fibrosis stage; platelet count; albumin; AST, ALT, and AFP levels; and HCV genotype (Table 2). Multivariate analysis was performed on these factors (Table 3), and the following were identified as independent risk factors: fibrosis stage (F4), AFP (6–20 and ≥ 20 ng/mL), age (≥ 57 years), and IFN therapy (SVR).

Development of HCC

During the follow-up period, HCC developed in 110 (15.6%) patients. Of the 110 patients with HCC, 58 (52.7%) were diagnosed with the disease by histological examination of biopsy-obtained or resected liver specimens. Of these 58 patients, 24 (41.3%) had hypovascular HCC.

Among the patients with HCC, only eight (7.2%) had AFP <6 ng/mL at the time of diagnosis of HCC. Figure 1 shows Kaplan–Meier estimates of the cumulative risk of HCC with respect to fibrosis stage at entry. The 10-year cumulative incidence rates of HCC for stages F0/F1, F2, F3, and F4 were 2.5, 12.8, 19.3, and 55.9%, respectively.

There were significant differences in cumulative incidence rates among the three groups of patients with different AFP levels. The 10-year cumulative risk of HCC was 6.0% in the 350 patients with AFP <6 ng/mL at the study entry, 24.6% in the 254 patients with AFP 6–20 ng/mL, and 47.3% in the 103 patients with AFP ≥ 20 ng/mL ($P < 0.001$) (Fig. 2). Of the 350 patients with AFP <6 ng/mL, 21 eventually developed HCC during the observation period. Fourteen of these 21 patients were ≥ 57 years old and 10 had fibrosis stage F3 or F4. In remarkable contrast, HCC ultimately developed in 84.5% of the patients with AFP ≥ 20 ng/mL.

The 10-year cumulative incidence rates of HCC were 3.1% in patients with SVR to IFN, 14.6% in patients with non-SVR, and 29.5% in the patients without IFN therapy (Fig. 3). Of the 139 patients with SVR, three (2.2%) eventually developed HCC during the observation period. These three patients had advanced fibrosis stages at the study entry (1 with F3 and 2 with F4). Figure 4 shows the cumulative incidence of HCC in the patients with different AFP levels, stratified by the fibrosis stage. In the patients with fibrosis stage F4, there were significant differences in HCC incidence between those with AFP levels of <6 and those with levels of ≥ 20 ng/mL.

Figure 5 shows the proportions of patients with different AFP levels stratified by the fibrosis stage. The proportion of patients with AFP <6 ng/mL decreased with the advance of fibrosis stage, and conversely, the proportion of patients with AFP ≥ 20 ng/mL increased with the advance of fibrosis stage. There was a strong correlation between AFP levels and the fibrosis stage.

Table 2 Factors increasing the risk for hepatocellular carcinoma (HCC), determined by univariate analysis

Features	Hazard ratio	P value
Age		
<57 years	1	
≥57 years	3.889	<0.001
Sex		
Female	1	
Male	1.146	0.475
Alcohol intake		
None	1	
Habitual	1.012	0.962
Interferon therapy		
None	1	
Non-SVR	0.523	0.002
SVR	0.063	<0.001
Fibrosis stage		
F0/F1	1	
F2	1.863	0.096
F3	3.985	<0.001
F4	13.045	<0.001
Platelet count		
≥150 × 10 ³ /mm ³	1	
<150 × 10 ³ /mm ³	4.644	<0.001
Albumin		
≥4.2 g/dL	1	
<4.2 g/dL	2.952	<0.001
Total bilirubin		
<0.7 mg/dL	1	
≥0.7 mg/dL	1.438	0.065
AST		
<53 IU/L	1	
≥53 IU/L	2.501	<0.001
ALT		
<82 IU/L	1	
≥82 IU/L	1.514	0.035
AFP		
<6 ng/mL	1	
6–20 ng/mL	4.628	<0.001
≥20 ng/mL	10.335	<0.001
HCV core antigen		
<1,000 fmol/L	1	
≥1,000 fmol/L	1.112	0.645
HCV genotype		
2a/2b	1	
1b	1.730	0.027

SVR sustained virological response

Table 3 Factors increasing the risk for HCC, determined by multivariate analysis

Features	Hazard ratio (95% CI)	P value
Fibrosis stage		
F0/F1	1	
F2	1.030 (0.471–2.253)	0.942
F3	1.682 (0.632–3.713)	0.198
F4	3.957 (1.861–8.411)	<0.001
AFP		
<6 ng/mL	1	
6–20 ng/mL	1.942 (1.066–3.538)	0.030
≥20 ng/mL	3.884 (2.014–7.433)	<0.001
Age		
<57 years	1	
≥57 years	2.026 (1.261–3.255)	0.004
Interferon therapy		
None	1	
Non-SVR	0.704 (0.453–1.094)	0.119
SVR	0.099 (0.029–0.334)	<0.001

CI confidence interval

Discussion

In the present study, four variables were identified as risk factors for HCC in patients with chronic HCV infection: fibrosis stage, AFP level, age, and IFN therapy. Previous reviews have analyzed risk factors for the development of HCC [3, 22–25]. Yoshida et al. [6] have reported that the annual incidence increases with the stage of liver fibrosis, from 0.5% in patients with stage F0 or F1 to 7.9% in patients with stage F4 (cirrhosis). In our study, the cumulative incidence of HCC increased along with the advance of fibrosis stage. AFP is used as a serological marker of HCC, and is employed in combination with US for screening HCC [3]. Several reports have shown an elevated AFP level as a risk factor for the development of HCC among patients infected with HCV [16, 25–32]. Most of the studied patients had cirrhosis that was not definitely diagnosed by clinical symptoms and ultrasonographic findings. There have been few studies on patients with chronic hepatitis C, in addition to those with cirrhosis [27]. Thus, it has been unclear whether elevated AFP levels are a risk factor for the development of HCC in patients infected with HCV. Against this background, we were prompted to analyze the utility of AFP as a risk factor for the development of HCC in patients who had been histologically diagnosed by US-guided liver biopsy. In the present study,

Fig. 1 Cumulative incidence of hepatocellular carcinoma (HCC) according to the fibrosis stage




Fig. 2 Cumulative incidence of HCC according to alpha-fetoprotein (AFP) levels





Fig. 3 Cumulative incidence of HCC according to interferon (IFN) therapy. SVR Sustained virological response







Fig. 4 Cumulative incidence of HCC according to AFP levels, stratified by the fibrosis stage

Fig. 5 Proportions of patients with three different AFP levels (<6 ng/mL, 6–20 ng/mL, and ≥20 ng/mL) at different fibrosis stages



among patients infected with HCV, including not only those with cirrhosis but also those with chronic hepatitis, we found AFP levels to be a dependable risk factor for HCC, in addition to the fibrosis stage. Of particular note, not only the patients with high AFP levels (≥20 ng/mL) but also those with even slightly elevated AFP levels (between 6 and 20 ng/mL) had increased risks for the development of HCC. In the patients in this study, the median AFP level was 6 ng/mL. It deviated slightly from serum levels of AFP in healthy adults that have been reported to range from 0.1 to 5.8 ng/mL [33]. Hence, we performed analyses by setting various AFP cutoff levels for

evaluating their performance as risk factors. However, there were no significant differences in the analysis with the use of AFP cutoff levels exceeding 7 ng/mL. On the basis of these observations, an AFP cutoff level of 6 ng/mL was adopted in this study. In previous reports, AFP levels were associated with advanced fibrosis stage in patients infected with HCV in the absence of HCC [34–38]. In the present study, AFP levels were elevated in parallel with advanced fibrosis stages and correlated well with the fibrosis stage. As the patients with even slightly elevated AFP levels, between 6 and 20 ng/mL, had moderately advanced liver fibrosis stages, these AFP levels could

indicate an elevated risk for HCC in patients with chronic HCV infection.

Hu et al. [36] found that an AFP level of 15.0 mg/mL could detect severe fibrosis with a sensitivity of 22.8% and specificity of 94.5%. Moreover, they reported, during observation for 6 months of patients with chronic hepatitis C, that AFP levels stayed within the normal range (<10 ng/mL) in 60%, were persistently elevated in 24%, and fluctuated in the remaining 15%. By multivariate analysis, they identified AST, INR, and fibrosis as risk factors for AFP levels of >10 ng/mL. In view of the correlation between AFP levels and fibrosis stages, the AFP level at the time of liver biopsy was taken into account in the analysis in the present study; ALT levels are reported to be persistently elevated in the majority (60%) of patients with chronic hepatitis C.

Liver biopsy is the gold standard for assessing hepatic fibrosis [8, 9]. However, the needle liver biopsy has a sampling error and is too invasive as a routine procedure [10, 11]. Therefore, AFP levels may be used as a noninvasive and predictive marker in place of the fibrosis stage. The platelet count is known to reflect the severity of chronic hepatitis C [12, 13], and is used to estimate the degree of fibrosis without resort to liver biopsy [12–14]. Previous reports have shown low platelet counts to represent a risk factor for HCC in cirrhotic patients [13, 15, 16]. Matsumura et al. [13] reported that age and serum platelet count were significant risk factors for the development of HCC, and as such, they were a major clinico-laboratory means of evaluating the fibrosis stage. In the present study, however, the platelet count was not an independent risk factor for HCC development. When Cox regression analysis was performed on variables other than the fibrosis stage, platelet count and serum albumin levels were identified as independent risk factors for the development of HCC (data not shown).

IFN has been used to treat patients with HCV infection. Failure to achieve an SVR to IFN-based therapies, and preexisting advanced hepatic fibrosis and/or cirrhosis, are major predictors of HCC [6, 23, 25, 39, 40]. In the present study, SVR emerged as an independent risk factor for the development of HCC, while non-SVR was not. However, the cumulative incidence rate of HCC in patients with non-SVR was lower than that in those without IFN therapy. These results suggest that the use of IFN in patients with HCV-related liver disease may be beneficial in preventing the development of HCC. Several Japanese cohort studies have demonstrated that IFN therapy reduces the incidence of HCC, not only in sustained virological responders but also in transient responders who have failed to eliminate HCV [6, 41–45]. In cirrhotic patients, Nishiguchi et al. [39] reported that the relative risk of patients with IFN- α treatment developing HCC was 0.067 in comparison with the control

group. In contrast, Valla et al. [46] could not prove any significant benefit for the prevention of HCC between patients with and without IFN treatment. Camma et al. [47] suggested a slight preventive effect of IFN on HCC development in patients with HCV-related cirrhosis. Shiffman et al. [48] have reported that continuous IFN therapy led to a decline in hepatic fibrosis despite the persistence of viremia. In addition, there are case reports that IFN therapy reduced AFP levels in virological nonresponders [49]. Murashima et al. [50] showed that IFN therapy, but not Strong Neo-Minophagen C (SNMC) (Glycyrrhizin, Tokyo, Japan), universally reduced basic AFP levels. In an *in vitro* study of the effects of IFN on an HCC cell line, IFN exhibited anti-tumor effects [51]. Taken together, these findings suggest that AFP levels may be useful for predicting the development of HCC during IFN-based treatments, including long-term low-dose IFN therapy.

There have been several reports on the relationship between chronological trends in platelet counts, AST or AFP levels, and the development of HCC [11, 26, 27, 52–54]. Tarao et al. [52, 53] showed that in patients with HCV-related cirrhosis, those with persistently high serum ALT levels had a high risk of developing HCC and multicentric carcinogenesis, whereas those with persistently low ALT levels faced a very low risk. Likewise, the dynamics of AFP levels in patients with chronic HCV infection may be useful to estimate the risk of developing HCC. Recently, Bruce et al. [32] found serial measurements of AFP helpful in identifying persons with advanced fibrosis. They used an AFP level of 8 ng/mL, the test manufacturer's upper limit of normal, as the evaluation of the risk of development of HCC. It is not certain whether or not AFP would be a risk factor of HCC development in patients with chronic liver disease of etiologies other than persistent HCV infection. Velazquez et al. [55] reported that an AFP level of >5 ng/mL at study entry was associated with the development of HCC in their univariate analysis but not in their multivariate analysis. They speculated that this could have been because the main causative factor of liver cirrhosis in their series was alcohol. Taken together, the findings of various studies suggest that the baseline AFP level may be more reliable as a predictive factor for the development of HCC in patients with HCV-related liver disease than in those with liver disease of other etiologies.

In conclusion, AFP is a noninvasive predictive marker for the development of HCC in patients infected with HCV. The present study indicates that not only high AFP levels (≥ 20 ng/mL) but also slightly elevated AFP levels, between 6 and 20 ng/mL, could indicate substantial risks for the development of HCC, complementing the fibrosis stage. In contrast, AFP levels of <6 ng/mL indicate a low risk of HCC development, irrespective of the liver fibrosis stage. IFN therapy significantly reduces the risk of the

development of HCC, especially in patients with an SVR to the therapy.

Acknowledgments This work was sponsored in part by grants from the Ministry of Health, Labour and Welfare of Japan.

References

- Afdhal NH. The natural history of hepatitis C. *Semin Liver Dis.* 2004;24(Suppl 2):3–8.
- Cohen J. Virology. Culture systems for hepatitis C virus in sight at last. *Science.* 2005;308:1539–41.
- Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. *Semin Liver Dis.* 2005;25:143–54.
- Alter MJ. Epidemiology of hepatitis C virus infection. *World J Gastroenterol.* 2007;13:2436–41.
- El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology.* 2007;132:2557–76.
- Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. *Ann Intern Med.* 1999;131:174–81.
- Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. *Gastroenterology.* 2004;127:S62–71.
- Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. *Hepatology.* 2001;33:196–200.
- Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. *Hepatology.* 2002;36:S161–72.
- Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol.* 2002;97:2614–8.
- Yu ML, Lin SM, Lee CM, Dai CY, Chang WY, Chen SC, et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. *Hepatology.* 2006;44:1086–97.
- Ono E, Shiratori Y, Okudaira T, Imamura M, Teratani T, Kanai F, et al. Platelet count reflects stage of chronic hepatitis C. *Hepatol Res.* 1999;15:192–200.
- Matsumura H, Moriyama M, Goto I, Tanaka N, Okubo H, Arakawa Y. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C—a study of 527 patients at one establishment. *J Viral Hepat.* 2000;7:268–75.
- Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. *Am J Gastroenterol.* 2001;96:3142–6.
- Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. *Gut.* 2000;47:131–6.
- Rodriguez-Diaz JL, Rosas-Camargo V, Vega-Vega O, Morales-Espinosa D, Mendez-Reguera A, Martinez-Tlahuel JL, et al. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study. *Clin Oncol (R Coll Radiol).* 2007;19:197–203.
- Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology.* 1994;19:1513–20.
- Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. *J Clin Microbiol.* 1999;37:1802–8.
- Tanaka E, Ohue C, Aoyagi K, Yamaguchi K, Yagi S, Kiyosawa K, et al. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. *Hepatology.* 2000;32:388–93.
- Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. *J Gen Virol.* 1993;74(Pt 11):2391–9.
- Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. *J Clin Microbiol.* 1997;35:201–7.
- Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. *Cancer.* 2000;89:53–9.
- Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology.* 2004;127:S35–50.
- Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, et al. Hepatocellular carcinoma: recent trends in Japan. *Gastroenterology.* 2004;127:S17–26.
- Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology.* 2005;42:1208–36.
- Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. *N Engl J Med.* 1991;325:675–80.
- Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. *N Engl J Med.* 1993;328:1797–801.
- Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. *Hepatology.* 1994;19:61–6.
- Ganne-Carrie N, Chastang C, Chapel F, Munz C, Pateron D, Sibony M, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. *Hepatology.* 1996;23:1112–8.
- Sangiovanni A, Colombo E, Radaelli F, Bortoli A, Bovo G, Casiraghi MA, et al. Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients. *Am J Gastroenterol.* 2001;96:1575–80.
- Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, Hosaka T, et al. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. *J Hepatol.* 2006;44:1089–97.
- Bruce MG, Bruden D, McMahon BJ, Christensen C, Homan C, Sullivan D, et al. Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients with chronic hepatitis C. *J Viral Hepat.* 2008;15:179–87.
- Taketa K. Alpha-fetoprotein: reevaluation in hepatology. *Hepatology.* 1990;12:1420–32.
- Chu CW, Hwang SJ, Luo JC, Lai CR, Tsay SH, Li CP, et al. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. *J Clin Gastroenterol.* 2001;32:240–4.

35. Lu LG, Zeng MD, Wan MB, Li CZ, Mao YM, Li JQ, et al. Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters. *World J Gastroenterol*. 2003;9:2574–8.
36. Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. *Am J Gastroenterol*. 2004;99:860–5.
37. Wilfredo Canchis P, Gonzalez SA, Isabel Fiel M, Chiriboga L, Yee H, Edlin BR, et al. Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein. *Liver Int*. 2004;24:198–203.
38. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C trial. *J Hepatol*. 2005;43:434–41.
39. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. *Lancet*. 1995;346:1051–5.
40. Yu ML, Huang CF, Dai CY, Huang JF, Chuang WL. Long-term effects of interferon-based therapy for chronic hepatitis C. *Oncology*. 2007;72(Suppl 1):16–23.
41. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. *Ann Intern Med*. 1998;129:94–9.
42. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. *Hepatology*. 1998;27:1394–402.
43. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. *Hepatology*. 1999;29:1124–30.
44. Okanoue T, Itoh Y, Kirishima T, Daimon Y, Toyama T, Morita A, et al. Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. *Hepatol Res*. 2002;23:62–77.
45. Hino K, Okita K. Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C. *J Antimicrob Chemother*. 2004;53:19–22.
46. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. *Hepatology*. 1999;29:1870–5.
47. Camma C, Di Bona D, Craxi A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. *Curr Pharm Des*. 2004;10:2123–30.
48. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. *Gastroenterology*. 1999;117:1164–72.
49. Stein DF, Myaing M. Normalization of markedly elevated alpha-fetoprotein in a virologic nonresponder with HCV-related cirrhosis. *Dig Dis Sci*. 2002;47:2686–90.
50. Murashima S, Tanaka M, Haramaki M, Yutani S, Nakashima Y, Harada K, et al. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. *Dig Dis Sci*. 2006;51:808–12.
51. Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, Akiba J, et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. *Hepatology*. 1999;29:1708–17.
52. Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. *Cancer*. 1999;86:589–95.
53. Tarao K, Rino Y, Ohkawa S, Tamai S, Miyakawa K, Takakura H, et al. Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis. *Cancer*. 2002;94:1787–95.
54. Moriyama M, Matsumura H, Aoki H, Shimizu T, Nakai K, Saito T, et al. Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy. *Intervirology*. 2003;46:296–307.
55. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. *Hepatology*. 2003;37:520–7.

Received: 2009.12.21
Accepted: 2010.07.07
Published: 2011.02.01

Authors' Contribution:

- A** Study Design
- B** Data Collection
- C** Statistical Analysis
- D** Data Interpretation
- E** Manuscript Preparation
- F** Literature Search
- G** Funds Collection

The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area

Naota Taura^{1ABCEFG}, Nobuyoshi Fukushima^{2ABCEFG}, Hiroshi Yatsuhashi^{1ABCEFG}, Yuko Takami^{3ABCEFG}, Masataka Seike^{4ABCEFG}, Hiroshi Watanabe^{5ABCEFG}, Toshihiko Mizuta^{6ABCEFG}, Yutaka Sasaki^{7ABCEFG}, Kenji Nagata^{8ABCEFG}, Akinari Tabara^{9ABCEFG}, Yasuji Komorizono^{10ABCEFG}, Akinobu Taketomi^{11ABCEFG}, Shuichi Matsumoto^{12ABCEFG}, Tsutomu Tamai^{13ABCEFG}, Toyokichi Muro^{14ABCEFG}, Kazuhiko Nakao^{15ABCEFG}, Kunitaka Fukuzumi^{16ABCEFG}, Tatsuji Maeshiro^{17ABCEFG}, Osami Inoue^{18ABCEFG}, Michio Sata^{2ABCEFG}

- ¹ Clinical Research Center, National Nagasaki Medical Center, Omura City, Nagasaki, Japan
- ² Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume City, Fukuoka, Japan
- ³ Department of Surgery, National Hospital Organization Kyushu Medical Center, Chuo-ku, Fukuoka City, Fukuoka, Japan
- ⁴ 1st Department of Internal Medicine, Oita University Faculty of Medicine, Hasama-machi, Yufu City, Oita, Japan
- ⁵ Department of Hepatology, Fukuoka Red Cross Hospital, Minami-ku, Fukuoka City, Fukuoka, Japan
- ⁶ Department of Internal Medicine, Saga University Faculty of Medicine, Saga City, Saga, Japan
- ⁷ Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto City, Kumamoto, Japan
- ⁸ Department of Internal Medicine II, Miyazaki Medical College, Kiyotake-cho, Miyazaki-gun, Miyazaki, Japan
- ⁹ 3rd Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyusyu City, Fukuoka, Japan
- ¹⁰ Department of Hepatology, Nanpuh Hospital, Kagoshima City, Kagoshima, Japan
- ¹¹ Department of Surgery and Science, Graduate school of medical sciences, Kyushu University, Fukuoka City, Fukuoka, Japan
- ¹² Department of Internal Medicine, Fukuoka Tokusukai Medical Center, Kasuga City, Fukuoka, Japan
- ¹³ Digestive Disease and Life-Style Related Disease, Health Research Human and Environmental Sciences, Kagoshima University, Kagoshima City, Kagoshima, Japan
- ¹⁴ Department of Gastroenterology, National Hospital Organization Oita Medical Center, Oita City, Oita, Japan
- ¹⁵ Department of Gastroenterology and Hepatology, Nagasaki University School of Medicine, Nagasaki City, Nagasaki, Japan
- ¹⁶ Department of Gastroenterology, National Hospital Organization, Kyushu Medical Center, Fukuoka City, Fukuoka, Japan
- ¹⁷ 1st Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus, Nakagami-gun, Okinawa, Japan
- ¹⁸ Department of Gastroenterology, Nagasaki Rousai Hospital, Sasebo City, Nagasaki, Japan

Source of support: Departmental sources

Background:	Summary The incidence of hepatocellular carcinoma (HCC) in Japan has still been increasing. The aim of the present study was to analyze the epidemiological trend of HCC in the western area of Japan, Kyushu.
Material/Methods:	A total of 10,010 patients with HCC diagnosed between 1996 and 2008 in the Liver Cancer study group of Kyushu (LCSK), were recruited for this study. Cohorts of patients with HCC were categorized into five year intervals. The etiology of HCC was categorized to four groups as follows; B: HBsAg positive, HCV-RNA negative, C: HCV-RNA positive, HBsAg negative, B+C: both of HBsAg and HCV-RNA positive, non-BC: both of HBsAg and HCV-RNA negative.
Results:	B was 14.8% (1,485 of 10,010), whereas 68.1% (6,819 of 10,010) had C, and 1.4% (140 of 10,010) had HCC associated with both viruses. The remaining 1,566 patients (15.6%) did not associate with both viruses. Cohorts of patients with HCC were divided into six-year intervals (1996–2001 and 2002–2007). The ratio of C cases decreased from 73.1% in 1996–2001 to 64.9% in 2002–2007. On the other hand, B and nonBC cases increased significantly from 13.9% and 11.3% in 1996–2001 to 16.2% and 17.6% in 2002–2007, respectively.
Conclusions:	The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased after 2001 in Kyushu area. This change was due to the increase in the number and proportion of the HCC not only nonBC patients but also B patients.
key words:	hepatitis virus • hepatocellular carcinoma • Japan
Full-text PDF:	http://www.medscimonit.com/fulltxt.php?ICID=881375
Word count:	1778
Tables:	3
Figures:	2
References:	32
Author's address:	Hiroshi Yatsuhashi, Clinical Research Center, National Nagasaki Medical Center, 2-1001-1 Kubara, Omura City, Nagasaki, Japan, e-mail: yatsuhashi@nmc.hosp.go.jp

BACKGROUND

The three leading causes of death in Japan are malignancy neoplasms, cardiovascular diseases, and cerebrovascular diseases. Since 1981, malignant neoplasms have been the leading cause of death in Japan. For the last 30 years, liver cancer has been the third leading cause of death from malignant neoplasms in men. In women, liver cancer has ranked fifth during the past decade [1]. Hepatocellular carcinoma (HCC) accounts for 85% to 90% of primary liver cancers [2] and the age-adjusted HCC mortality rate has increased in recent decades in Japan [3]. Similarly, a trend of increasing rates of HCC has been reported from several developed countries in North America, Europe and Asia [4,5]. HCC often develops in patients with liver cirrhosis caused by hepatitis B virus (HBV), hepatitis C virus (HCV), excessive alcohol consumption, or nonalcoholic fatty liver disease. Of the hepatitis viruses which cause HCC, HCV is predominant in Japan [6–9].

Although the age-adjusted incidence of HCC has increased in Japan, sequential changes in etiology of HCC patients between 2001 and 2008 are not fully understood [10]. To clarify factors affecting epidemiological changes in Japanese HCC patients, especially the recent trend of HCC, we analyzed the epidemiological trend of HCC in the western area of Japan, Kyushu area.

MATERIAL AND METHODS

Patients

A total of 10,010 patients with HCC diagnosed between 1996 and 2008 in the Liver Cancer study group of Kyushu (LCSK), were recruited for this study. The diagnosis of HCC was based on AFP levels and imaging techniques including ultrasonography (USG), computerized tomography (CT), magnetic resonance imaging (MRI), hepatic angiography (HAG), and/or tumor biopsy. The diagnostic criteria for HCC were either a confirmative tumor biopsy or elevated AFP (>20 ng/mL) and neovascularization in HAG and/or CT.

Etiology of HCC

A diagnosis of chronic HCV infection was based on the presence of HCV-RNA detected by polymerase chain reaction (PCR), whereas diagnosis of chronic HBV infection was based on the presence of hepatitis B surface antigen (HBsAg). The etiology of HCC was categorized to four groups as follows; **B**: HBsAg positive, HCV-RNA negative, **C**: HCV-RNA positive, HBsAg negative, **B+C**: both of HBsAg and HCV-RNA positive, **nonBC**: both of HBsAg and HCV-RNA negative.

Statistical analysis

The data were analyzed by the Mann-Whitney test for the continuous ordinal data, the χ^2 test with Yates' correction and the Fisher exact test for the association between two qualitative variables. The standard deviation was calculated based on the binomial model for the response proportion. $P < 0.05$ was considered statistically significant.

RESULTS

Clinical features of the studied patients

A total of 10,010 patients with HCC were diagnosed at our study group from 1996 to 2008. Table 1 show that the proportion of patients diagnosed with **B** was 14.8% (1,485 of 10,010), whereas 68.1% (6,819 of 10,010) had **C**, and an additional 1.4% (140 of 10,010) had HCC associated with both viruses. The remaining 1,566 patients (15.6%) did not associate with both viruses. In analysis of patients in HCC by category, the median age of patients at diagnosis of **B** was 57 years old significant younger than other types HCC (**C**: 69, **nonBC**: 70, **B+C** 65 years old).

As shown in Figures 1 and 2, the number and ratio of **B** cases remained unchanged from 1996 to 2001 and thereafter increased and plateaued, whereas **C** rapidly increased from 1996 to 2000 and thereafter decreased and plateaued. In addition, the number and ratio of the **nonBC** cases has increased continued gradually and continued in this study period.

Change of etiology in patients with HCC during the period 1996–2007 with 6-years intervals

Cohorts of patients with HCC were divided into six-year intervals (1996–2001 and 2002–2007). Table 2 show that the incident rate of **C** decreased significantly from 73.1% in 1996–2001 to 64.9% in 2002–2007 (1996–2001 vs. 2002–2007, $p < 0.001$). On the other hand, the incident rate of **B** and **nonBC** increased significantly from 13.9% and 11.3% in 1996–2001 to 16.2% and 17.6% in 2002–2007, respectively. Not only the incident rate but also number of **B** and **nonBC** became larger in same 6 years periods.

Table 3 shows that male/female ratio of **C** and **nonBC** decreased significantly from 2.2 and 4.0 in 1996–2001 to 1.8 and 2.7 in 2002–2007, respectively ($p < 0.001$). The ratio became clearly smaller, indicates an increase in female patients with **C** and **nonBC**. On the other hand, the male/female ratio of **B** patients did not significantly change during the period. The median age at diagnosis of **B**, **C**, and **nonBC** in six-year intervals were significant increase from 56 to 58, from 67 to 71 and from 68 to 71 years of age during the period.

DISCUSSION

Our study was the twenty-three major liver center-based study designed to examine the sequential change in the background of HCC patients during the past 13 years, 1996–2008. More than 80% of our patients had chronic HBV or HCV infections. During this observation period, the number and proportion of HCC-C reached a peak in 2000 and thereafter decreased and became stabilized. Previous studies from Japan reported that the proportion of the HCC patients with HCV infection had been increased and reached a plateau in the period of 1981–2001 [1,3,10–12]. However, in our study, the number and proportion of the HCC patients with HCV infection cases decreased in 2001–2008. The reason may be explained as follows; interferon therapy for chronic hepatitis C may have been associated with a decreased incidence of HCC [13–17]. Oral supplementation with a oral branched-chain amino acids has been useful in the prevention HCC [18]. Finally, the chronically HCV-infected

Table 1. The characteristic of HCC patients during the period of 1996–2008.

Age (y.o.)	B		C		nonB		B+C		Total
	Male	Female	Male	Female	Male	Female	Male	Female	
0–	1	0	0	1	0	0	0	0	2
10–	4	1	0	0	0	2	0	0	7
20–	6	2	1	0	1	1	0	0	11
30–	31	5	4	0	11	3	2	0	56
40–	204	22	130	12	32	15	12	0	427
50–	507	66	728	145	167	32	31	6	1,682
60–	287	118	1836	741	411	102	35	13	3,543
70–	140	64	1775	947	483	133	22	14	3,578
80–	9	18	271	214	97	65	1	4	679
90–	0	0	9	5	9	2	0	0	58
Total	1,189	296	4,754	2,065	1,211	355	103	37	10,010
	1,485 (4.8%)		6,819 (68.1%)		1,566 (15.6%)		140 (1.4%)		
Median	57	63	67	70	68	70	61	68	67
	57		69		70		65		
Mean	56	64	68	71	69	71	62	68	67
	58		68		68		63		
Range	1–87	14–89	27–94	0–93	28–96	17–90	36–82	55–82	0–96
	1–89		0–94		17–96		36–82		

Age: B vs. C $p \leq 0.001$; B vs. B+C $p \leq 0.001$; B vs. nonBC $p \leq 0.001$; C vs. BC $p \leq 0.001$; C vs. nonBC $p = 0.043$; BC vs. nonB+C $p \leq 0.001$. IQR – interquartile range; SD – standard deviation.




Figure 1. Sequential changes in the number of HCC patients categorized by etiology during the period 1996–2008.

population is aging in Japan. Yoshizawa et al. reported that age-specific prevalence for the presence of HCVAb among ~300,000 voluntary blood donors from Hiroshima in 1999 clearly increased with the age, reaching the highest proportion of 7% in individuals who were more than 70 years old [10,19]. In this study, the median age of the HCC patients with HCV infection steadily increased from 67 to 71 years of age during the studied period. In a word, HCV infected

people become older with years in Japan and they were regarded as a high risk for HCC.

The prevalence rate of HBV in Kyushu area has been reported to be higher than other area in Japan [1]. In Kyushu area, 95% of patients with chronic HBV infection had HBV genotype C except for Okinawa [20]. HBV genotype C is thought to be associated with higher incidence of HCC

PH




Figure 2. Sequential changes in the ratio of HCC patients categorized by etiology during the period 1996–2008.

Table 2. Change of etiology in patients with HCC during the period 1996–2007 with 6-years intervals.

Period	1996–2001	2002–2007	P value
Number	3,023	4,173	
Sex			
Male	2,162	2,849	
Female	861	1,324	
Ratio (male/female)	2.5	2.2	0.003
Age (y.o.) (IQR)	66 (14)	69 (12)	<0.001
Hepatitis virus (%)			
B	13.9	16.2	
C	73.1	64.9	
B+C	1.7	1.3	
nonBC	11.3	17.6	0.001

QR – interquartile range.

compared with other HBV genotypes [21]. In the present study, the incident rate of HCC patients with HBV infection became larger in this study period. To explain this change, we must consider from two viewpoints. The one is that the number of patients with HCC caused by HCV infection decreased, the other is that the proportion of chronic HBV infected patients who have reached the age of developing HCC is relatively high as described below.

Nationwide health survey for HBsAg in the over 40 years of age population had been done between 2002 and 2006 in Japan. This survey reports indicated that the average HBsAg prevalence was 1.2% in the total Japanese population patients with chronic HBV infection [10] and the age-specific prevalence of HBsAg was higher in the group aged between 50 (1.4%) and 55 years (1.5%). In the HCC patients with HBV genotype C, the mean age was 55 years in Japan [20]. This overlap between age-specific prevalence and hepatocellular carcinogenic age would be associated with the increase of HCC patients with HBV infection. Nucleoside analogue reverse transcriptase inhibitor (NARTI) therapy effectively reduces the incidence of HCC in chronic hepatitis B patients [22,23]. However, Interferon therapy for

Table 3. The median age and male/female ratio of HCC patients during the period of 1996–2007.

Period	1996–2001	2002–2007	P value
B			
Age (y.o.) (IQR)	56 (14)	58 (15)	0.001
Sex			
Male	331	519	
Female	88	157	
Ratio (male/female)	3.8	3.3	0.391
C			
Age (y.o.) (IQR)	67 (9)	71 (11)	<0.001
Sex			
Male	1,524	1,753	
Female	687	955	
Ratio (male/female)	2.2	1.8	0.002
nonBC			
Age (y.o.) (IQR)	68 (12)	71 (13)	<0.001
Sex			
Male	273	534	
Female	69	201	
Ratio (male/female)	4.0	2.7	0.012

QR – interquartile range.

chronic hepatitis C started from 1992, whereas NARTI therapy for HBV started from 2000 in Japan [24,25]. Hence, HBV associated HCC will probably decrease in Japan during the next 10 to 20 years.

The survey of HCC patients associated with nonBC infection in Japan was conducted by Inuyama Hepatitis Research Group from 1995 to 2003. The ratio of HCC patients with nonBC accounted 9.3% [1]. In the present study, the ratio of HCC patients with nonBC was 14.1%. Furthermore, the number and the proportion of HCC patients with nonBC have been gradually increasing in the periods. The current two studies account for the increase in number and proportion of HCC patients with nonBC. First, Lai et al. reported

that type 2 diabetes increases the risk of developing HCC in those who are HCV negative or have a high level of total cholesterol [26]. Second, Nakano et al. reported that epidemiological studies on diabetes mellitus revealed that the number of patients with diabetes mellitus is gradually increasing in Japan along with development of car society and westernization of food intake. Since prevalence of diabetes mellitus increases with aging, proportion of individuals with diabetes mellitus aged over 60 has exceeded two-third of estimated total number of patients (7.40 million in 2002) in Japan where aging of society is rapidly progressing [27]. In a word, the number of type 2 diabetes people is increasing in Japan and they were regarded as a high risk for HCC. Then, the number and the proportion of HCC patients with nonBC have been increased recent twelve years in Japan.

It is known that 2 to 4 decades of chronic HCV infection are required to develop cirrhosis and subsequent HCC [28–31]. The number of HCC cases has increased in Japan, because individuals infected with HCV during the past have grown old and have reached the cancer-bearing age. The prevalence of HCV infection in young Japanese individuals is low and the incidence of HCVAb is very low because of preventative actions against HCV infection such as the screening of blood products for HCV and the use of sterile medical equipment [32]. Additionally, we showed that the number and proportion of patients with HCC-C cases decreased, whereas the number and ratio of HCC-nonBC steadily increased during the studied period. These findings may be expected that the incidence of HCC patients with nonBC in Japan may continue to increase even after the consequence of the HCV epidemic level off, a country that is far advanced with regard to HCC patients with HCV infection, in the near future.

CONCLUSIONS

In summary, HCC patients had increased from 1996 to 2000 and this increase was originated from HCC patients with HCV infection. The number and proportion of HCC patients with HCV infection reached a peak in 2000 and thereafter decreased and became stabilized. The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased after 2001 in Kyushu area. This change was due to the increase in the number and proportion of the HCC not only nonBC patients but also B patients.

REFERENCES:

- Umemura T, Kiyosawa K: Epidemiology of hepatocellular carcinoma in Japan. *Hepatol Res*, 2007; 37(Suppl.2): S95–100
- El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology*, 2007; 132: 2557–76
- Kiyosawa K, Tanaka E: Characteristics of hepatocellular carcinoma in Japan. *Oncology*, 2002; 62: 5–7
- McGlynn KA, Tsao L, Hsing AW et al: International trends and patterns of primary liver cancer. *Int J Cancer*, 2001; 94: 290–96
- Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: worldwide incidence and trends. *Gastroenterology*, 2004; 127: S5–16
- Hamasaki K, Nakata K, Tsutsumi T et al: Changes in the prevalence of hepatitis B and C infection in patients with hepatocellular carcinoma in the Nagasaki Prefecture, Japan. *J Med Virol*, 1993; 40: 146–49
- Kato Y, Nakata K, Omagari K et al: Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. *Cancer*, 1994; 74: 2234–38
- Shiratori Y, Shiina S, Imamura M et al: Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. *Hepatology*, 1995; 22: 1027–33
- Shiratori Y, Shiina S, Zhang PY et al: Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan? *Cancer*, 1997; 80: 2060–67
- Kiyosawa K, Umemura T, Ichijo T et al: Hepatocellular carcinoma: recent trends in Japan. *Gastroenterology*, 2004; 127: S17–26
- Taura N, Yatsuhashi H, Hamasaki K et al: Increasing hepatitis C virus-associated hepatocellular carcinoma mortality and aging: Long term trends in Japan. *Hepatol Res*, 2006; 34: 130–34
- Taura N, Hamasaki K, Nakao K et al: Aging of patients with hepatitis C virus-associated hepatocellular carcinoma: long-term trends in Japan. *Oncol Rep*, 2006; 16: 837–43
- Nishiguchi S, Kuroki T, Nakatani S et al: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. *Lancet*, 1995; 346: 1051–55
- Nishiguchi S, Shiomi S, Nakatani S et al: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. *Lancet*, 2001; 357: 196–97
- Kasahara A, Hayashi N, Mochizuki K et al: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. *Osaka Liver Disease Study Group. Hepatology*, 1998; 27: 1394–402
- Ikeda K, Saitoh S, Arase Y et al: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. *Hepatology*, 1999; 29: 1124–30
- Makiyama A, Itoh Y, Kasahara A et al: Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. *Cancer*, 2004; 101: 1616–22
- Muto Y, Sato S, Watanabe A et al: Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. *Clin Gastroenterol Hepatol*, 2005; 3: 705–13
- Yoshizawa H: Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. *Oncology*, 2002; 62: 8–17
- Orito E, Mizokami M: Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. *Intervirology*, 2003; 46: 408–12
- Orito E, Mizokami M: Differences of HBV genotypes and hepatocellular carcinoma in Asian countries. *Hepatol Res*, 2007; 37: S33–35
- Matsumoto A, Tanaka E, Rokuhara A et al: Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic. *Hepatol Res*, 2005; 32(3): 173–84
- Xu J, Shi J, Wang YP et al: Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for. *Med Sci Monit*, 2009; 15(6): CR274–79
- Hayashi N, Takehara T: Antiviral therapy for chronic hepatitis C: past, present, and future. *J Gastroenterol*, 2006; 41(1): 17–27
- Kumashiro R, Kuwahara R, Ide T et al: Subclones of drug-resistant hepatitis B virus mutants and the outcome of breakthrough hepatitis in patients treated with lamivudine. *Intervirology*, 2003; 46(6): 350–54
- Lai MS, Hsieh MS, Chiu YH, Chen TH: Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. *Hepatology*, 2006; 43: 1295–302
- Nakano T, Ito H: Epidemiology of diabetes mellitus in old age in Japan. *Diabetes Res Clin Pract*, 2007; 77(Suppl.1): S76–81
- Deuffic S, Poynard T, Valleron AJ: Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. *J Viral Hepat*, 1999; 6: 411–13
- El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. *N Engl J Med*, 1999; 340: 745–50
- Planas R, Ballesta B, Antonio Alvarez M et al: Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. *J Hepatol*, 2004; 40: 823–30
- Davila JA, Morgan RO, Shaib Y et al: Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. *Gastroenterology*, 2004; 127: 1372–80
- Sasaki F, Tanaka J, Moriya T et al: Very low incidence rates of community-acquired hepatitis C virus infection in company employees, long-term inpatients, and blood donors in Japan. *J Epidemiol*, 1996; 6: 198–203

PH